Printer Friendly
The Free Library
14,716,107 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Aldagen and Texas Heart Institute to Begin Clinical Study of Stem Cell Therapy for Advanced Heart Failure Patients; FDA Clears IND to Begin Clinical Study.


DURHAM, N.C. -- Aldagen, Inc. today announced that the U.S. Food and Drug Administration (FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
) has cleared a clinical study for physicians led by Dr. Emerson Perin and Dr. James Willerson of the Texas Heart Institute at St. Luke's Episcopal Hospital This hospital-related article is a stub. You can help Wikipedia by [expanding it].

St.
 in Houston, Texas, to conduct a clinical trial using Aldagen's ALDESORT product to isolate a unique stem cell stem cell

In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult.
 population for therapy for advanced heart failure patients. It will be the first clinical trial involving this unique cell population for therapy for heart failure patients in the United States.

"We are very excited about the FDA clearance to begin this work in the Texas Medical Center at the Texas Heart Institute and St. Luke's. We believe these cells have the potential to find a very important place in the future treatment of patients with heart and vascular disease," said Drs. Willerson and Perin. Dr. James Willerson is president-elect and medical director of the Texas Heart Institute at St. Luke's and President of The University of Texas Health Sciences Center at Houston. Dr. Perin is director of New Cardiovascular Interventional Technology and director of the Stem Cell Center at the Texas Heart Institute at St. Luke's.

Drs. Willerson and Perin have been conducting a clinical trial in the United States using unfractionated bone marrow cells. Using a special catheter which is threaded through the groin, the doctors use an innovative mapping technology to identify areas in the heart which have sustained mechanical and electrical damage. Using that same catheter, doctors have injected millions of these bone marrow cells directly into the muscle of the left ventricle left ventricle
n.
The chamber on the left side of the heart that receives the arterial blood from the left atrium and contracts to force it into the aorta.
 along the periphery of the damaged area. The procedure, which is conducted in a few hours, has yielded promising results.

ALDESORT isolates a highly potent population of stem cells taken from the patient's own bone marrow. These cells are more active in restoring blood flow to damaged tissue than unfractionated bone marrow in pre-clinical animal models. These stem cells have the potential to build new blood vessels (angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization.

an·gi·o·gen·e·sis
n.
) in damaged hearts which could ultimately lead to improved functional improvement in advanced heart failure patients.

The first pilot phase of the study, which involves ten patients, is designed primarily to test for safety. In all, up to 60 patients will be enrolled in the study and randomized ran·dom·ize  
tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es
To make random in arrangement, especially in order to control the variables in an experiment.
, with half of them receiving stem cells isolated by ALDESORT.

"We are delighted to be working with a leading institute like the Texas Heart Institute at St. Luke's for our first cardiovascular stem cell therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs  trial. We look forward to initiating the trial and determining whether the injection of ALDESORT isolated stem cells can improve the health of heart failure patients," added Ed Field, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Aldagen.

For more information, call the Texas Heart Institute's Heart Information Center at 1-800-292-2221, visit online at www.texasheart.org/stemcell or e-mail directly to plea@heart.thi.tmc.edu.

About Aldagen, Inc.

Aldagen's proprietary products identify and isolate unique populations of adult stem cells with the potential to revolutionize treatments of cardiovascular disease and degenerative diseases. The Company is now testing these products in clinical trials. To learn more about Aldagen's products for preparing optimal cell populations for adult stem cell therapy, the Company invites you to visit its website at www.aldagen.com.

About The Texas Heart Institute and St. Luke's

World-renowned cardiovascular surgeon Denton A. Cooley, M.D., founded the Texas Heart Institute in 1962. The Texas Heart Institute is dedicated to reducing the devastating dev·as·tate  
tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates
1. To lay waste; destroy.

2. To overwhelm; confound; stun: was devastated by the rude remark.
 toll of cardiovascular disease through innovative programs in research, education and improved patient care. Together with the Institute's clinical partner, St. Luke's Episcopal Hospital, it has been ranked among the nation's top 10 heart centers in an annual survey published by U.S. News & World Report U.S. News & World Report

Weekly newsmagazine published in Washington, D.C. U.S. News was founded in 1933 by David Lawrence (1888–1973) to cover important domestic events; he founded World Report in 1945 to treat world news. The two magazines were merged in 1948.
 for the past 15 years.

St. Luke's Episcopal Health System comprises the flagship St. Luke's Episcopal Hospital in the Texas Medical Center, founded in 1954 by the Episcopal Diocese of Texas The Episcopal Diocese of Texas is one of the largest dioceses of the Episcopal Church in the United States of America. The diocese consists of all ECUSA congregations in the southeastern quartile of Texas, including the cities of Austin, Beaumont, Galveston, Houston (the see city) ; St. Luke's Community Medical Center - The Woodlands, opened in 2003; St. Luke's Episcopal Health Charities, a charity devoted to assessing and enhancing community health, especially among the underserved; and Kelsey-Seybold Management, LLP LLP - Lower Layer Protocol , overseeing 21 area clinic locations. St. Luke's Episcopal Hospital is home to the Texas Heart Institute, founded in 1962 by Denton A. Cooley, M.D., and consistently ranked among the top 10 cardiology and heart surgery centers in the nation by U.S. News and World Report. Affiliated with several nursing schools and two medical schools, St. Luke's serves as the primary adult teaching hospital for Baylor College of Medicine Baylor College of Medicine is a private medical school located in Houston, Texas, USA on the grounds of the Texas Medical Center. It has been consistently rated the top medical school in Texas and among the best in the United States. . St. Luke's was the first hospital in Texas named a Magnet hospital for nursing excellence, and the Health System has been recognized by FORTUNE as among "100 Best Companies to Work For" (2002, 2004 and 2005) and by Houston Business Journal as a top employer in Houston for three consecutive years.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
dramin
DR.AMIN MD. KAMRUL ALAM (Member): about research 8/5/2009 1:06 AM
sir,is there any scope for us to do research with you..Dr.AMIN MD>KAMRUL ALAM, Fellow trainee,National Heart Institute, Kuala Lumpur, Malaysia,,<br>amin_kamrul@hotmail.com

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 21, 2006
Words:808
Previous Article:RehabCare Appoints Jay W. Shreiner New Chief Financial Officer.
Next Article:CRA International Designs and Conducts Germany's First Virtual Power Plant Auction.(Company Profile)
Topics:



Related Articles
Rebuilding the heart: marrow cells boost cardiac recovery.(This Week)
Osiris Reaches Safety Milestone in Stem Cell Clinical Trial for Cardiac Patients.
Most End-Stage Heart Disease Patients Show Significant Improvement after Adult Stem Cell Treatment; Interim Clinical Data from TheraVitae Study...
First Patients Enrolled in St. Jude Medical's Study Looking at AF Suppression Pacing in Heart Failure Patients.
Arteriocyte Initiates Phase One Clinical Trial with $1.4 Million NIH STTR Grant; Cleveland Cell-Therapy Start-Up Among the First to Target Heart...
Have stem cells finally arrived? Despite fraud and controversy, signs point to an emerging, money-making industry.(BIOTECHNOLOGY)
Gentium Receives First IRB Approval to Begin U.S. Phase III Trial with Defibrotide to Treat Veno-Occlusive Disease with Multiple-Organ Failure.
Arteriocyte Inc. Completes Phase I Stem Cell Clinical Trial Enrollment; Will Present Update at TCT2006 Meeting.
First Heart Patient Treated in Adipose Stem Cell Trial; Cytori's Cardiovascular Stem Cell Study Initiated.
Ventracor Investor Update March 2007.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles